H J Wanebo1, J Lee2, B A Burtness3, J A Ridge4, M Ghebremichael2, S A Spencer5, D Psyrri6, E Pectasides6, D Rimm6, F R Rosen7, M R Hancock8, K A Tolba9, A A Forastiere10. 1. Department of Surgery, Landmark Medical Center, Woonsocket. Electronic address: hwanebo@chartercare.org. 2. Department of Biostatistics & Computational Biology, Dana Farber Cancer Institute, Boston. 3. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia. 4. Department of Surgery, Fox Chase Cancer Center, Philadelphia. 5. Department of Radiation Oncology, University of Alabama, Birmingham. 6. Department of Medicine, Yale University, New Haven. 7. Department of Medical Oncology, John H. Stroger Hospital of Cook County, Chicago. 8. Department of Medical Oncology, Porter Memorial Hospital, Denver. 9. Department of Medicine, University of Miami, Miami. 10. Department of Medical Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA.
Abstract
BACKGROUND: E2303 evaluated cetuximab, paclitaxel, and carboplatin used as induction therapy and concomitant with radiation therapy in patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) determining pathologic complete response (CR), event-free survival (EFS), and toxicity. PATIENTS AND METHODS: Patients with resectable stage III/IV HNSCC underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, patients completed CRT (68-72 Gy); otherwise, resection was carried out. p16 protein expression status was correlated with response/survival. RESULTS: Seventy-four patients were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no tumor (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible patients completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 patients (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 patients (8%). There were no treatment-related deaths. Toxicity was primarily hematologic or radiation-related. p16 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, paclitaxel, and carboplatin followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.
BACKGROUND: E2303 evaluated cetuximab, paclitaxel, and carboplatin used as induction therapy and concomitant with radiation therapy in patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) determining pathologic complete response (CR), event-free survival (EFS), and toxicity. PATIENTS AND METHODS: Patients with resectable stage III/IV HNSCC underwent induction therapy with planned primary site restaging biopsies (at week 8 in clinical complete responders and at week 14 if disease persisted). Chemoradiation (CRT) began week 9. If week 14 biopsy was negative, patients completed CRT (68-72 Gy); otherwise, resection was carried out. p16 protein expression status was correlated with response/survival. RESULTS: Seventy-four patients were enrolled; 63 were eligible. Forty-four (70%) were free of surgery to the primary site, progression, and death 1-year post-treatment. Following induction, 41 (23 CR) underwent week 8 primary site biopsy and 24 (59%) had no tumor (pathologic CR). Week 14 biopsy during chemoradiation (50 Gy) in 34 (15 previously positive biopsy; 19 no prior biopsy) was negative in 33. Thus 90% of eligible patients completed CRT. Overall survival and EFS were 78% and 55% at 3 years, respectively. Disease progression in 23 patients (37%) was local only in 10 (16%), regional in 5 (8%), local and regional in 2 (3%), and distant in 5 patients (8%). There were no treatment-related deaths. Toxicity was primarily hematologic or radiation-related. p16 AQUA score was not associated with response/survival. CONCLUSIONS: Induction cetuximab, paclitaxel, and carboplatin followed by the same drug CRT is safe and induces high primary site response and promising survival. CLINICAL TRIALS NUMBER: NCT 00089297.
Authors: Athanassios Argiris; Dwight E Heron; Ryan P Smith; Seungwon Kim; Michael K Gibson; Stephen Y Lai; Barton F Branstetter; Donna M Posluszny; Lin Wang; Raja R Seethala; Sanja Dacic; William Gooding; Jennifer R Grandis; Jonas T Johnson; Robert L Ferris Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Amanda Psyrri; Ziwei Yu; Paul M Weinberger; Clarence Sasaki; Bruce Haffty; Robert Camp; David Rimm; Barbara Ann Burtness Journal: Clin Cancer Res Date: 2005-08-15 Impact factor: 12.531
Authors: Klaus Dittmann; Claus Mayer; Birgit Fehrenbacher; Martin Schaller; Uma Raju; Luka Milas; David J Chen; Rainer Kehlbach; H Peter Rodemann Journal: J Biol Chem Date: 2005-07-05 Impact factor: 5.157
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: K Kian Ang; Brian A Berkey; Xiaoyu Tu; Hua-Zhong Zhang; Ruth Katz; Elizabeth H Hammond; Karen K Fu; Luka Milas Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Merrill S Kies; Floyd Christopher Holsinger; J Jack Lee; William N William; Bonnie S Glisson; Heather Y Lin; Jan S Lewin; Lawrence E Ginsberg; Katharine A Gillaspy; Erminia Massarelli; Lauren Byers; Scott M Lippman; Waun K Hong; Adel K El-Naggar; Adam S Garden; Vassiliki Papadimitrakopoulou Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Maura L Gillison; Qiang Zhang; Richard Jordan; Weihong Xiao; William H Westra; Andy Trotti; Sharon Spencer; Jonathan Harris; Christine H Chung; K Kian Ang Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Mai Takahashi; Michael Hwang; Krysztof Misiukiewicz; Vishal Gupta; Brett A Miles; Richard Bakst; Eric Genden; Isaiah Selkridge; John Botzler; Vruti Virani; Erin Moshier; Marcelo R Bonomi; Marshall R Posner Journal: Front Oncol Date: 2022-04-08 Impact factor: 5.738
Authors: Benoist Chibaudel; Roger Lacave; Marine Lefevre; Patrick Soussan; Martine Antoine; Sophie Périé; Jean-Baptiste Belloc; Alain Banal; Sébastien Albert; Frédéric Chabolle; Philippe Céruse; Philippe Baril; Michel Gatineau; Martin Housset; Rachel Moukoko; Magdalena Benetkiewicz; Aimery de Gramont; Franck Bonnetain; Jean Lacau St Guily Journal: Cancer Med Date: 2015-02-14 Impact factor: 4.452